These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 37093883

  • 1. Impact of uptake time on image quality of [68 Ga]Ga-PSMA-11 PET/CT.
    van der Sar ECA, Viol SLM, Braat AJAT, van Rooij R, Lam MGEH, de Jong HWAM, de Keizer B.
    Med Phys; 2023 Dec; 50(12):7619-7628. PubMed ID: 37093883
    [Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Dec; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3. Determination of optimal 68 Ga-PSMA PET/CT imaging time in prostate cancers by total-body dynamic PET/CT.
    Wen J, Zhu Y, Li L, Liu J, Chen Y, Chen R.
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2086-2095. PubMed ID: 34962583
    [Abstract] [Full Text] [Related]

  • 4. Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines.
    Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Williams J, Calais J.
    J Nucl Med; 2020 Mar; 61(3):405-411. PubMed ID: 31541035
    [Abstract] [Full Text] [Related]

  • 5. 68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer.
    Vinsensia M, Chyoke PL, Hadaschik B, Holland-Letz T, Moltz J, Kopka K, Rauscher I, Mier W, Schwaiger M, Haberkorn U, Mauer T, Kratochwil C, Eiber M, Giesel FL.
    J Nucl Med; 2017 Dec; 58(12):1949-1955. PubMed ID: 28637799
    [Abstract] [Full Text] [Related]

  • 6. How accurate is 68Gallium-prostate specific membrane antigen positron emission tomography / computed tomography (68Ga-PSMA PET/CT) on primary lymph node staging before radical prostatectomy in intermediate and high risk prostate cancer? A study of patient- and lymph node- based analyses.
    Erdem S, Simsek DH, Degirmenci E, Aydin R, Bagbudar S, Ozluk Y, Sanli Y, Sanli O, Ozcan F.
    Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
    [Abstract] [Full Text] [Related]

  • 7. Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions.
    Uprimny C, Kroiss AS, Decristoforo C, Fritz J, Warwitz B, Scarpa L, Roig LG, Kendler D, von Guggenberg E, Bektic J, Horninger W, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):765-775. PubMed ID: 27900519
    [Abstract] [Full Text] [Related]

  • 8. Head-to-Head Comparison of 68Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10-Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients.
    Schilham MGM, Zamecnik P, Privé BM, Israël B, Rijpkema M, Scheenen T, Barentsz JO, Nagarajah J, Gotthardt M.
    J Nucl Med; 2021 Sep 01; 62(9):1258-1263. PubMed ID: 33517328
    [Abstract] [Full Text] [Related]

  • 9. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
    Prasad V, Steffen IG, Diederichs G, Makowski MR, Wust P, Brenner W.
    Mol Imaging Biol; 2016 Jun 01; 18(3):428-36. PubMed ID: 27038316
    [Abstract] [Full Text] [Related]

  • 10. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT.
    Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, Pfannenberg C, la Fougère C.
    Eur J Nucl Med Mol Imaging; 2017 Jan 01; 44(1):92-101. PubMed ID: 27557844
    [Abstract] [Full Text] [Related]

  • 11. Combined whole-body dynamic and static PET/CT with low-dose [18F]PSMA-1007 in prostate cancer patients.
    Sachpekidis C, Pan L, Groezinger M, Strauss DS, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol Imaging; 2024 Jun 01; 51(7):2137-2150. PubMed ID: 38286936
    [Abstract] [Full Text] [Related]

  • 12. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep 01; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

  • 13. Primary lymph-node staging with 68Ga-PSMA PET in high-risk prostate cancer: pathologic correlation with extended pelvic lymphadenectomy specimens.
    Corona-Montes VE, González-Cuenca E, Fernández-Noyola G, Olarte-Casas MA, Bobadilla-Salazar D, Medrano-Urtecho HM, Asimakopoulos AD.
    Urol Oncol; 2021 Aug 01; 39(8):494.e1-494.e6. PubMed ID: 33223371
    [Abstract] [Full Text] [Related]

  • 14. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
    Luiting HB, van Leeuwen PJ, Busstra MB, Brabander T, van der Poel HG, Donswijk ML, Vis AN, Emmett L, Stricker PD, Roobol MJ.
    BJU Int; 2020 Feb 01; 125(2):206-214. PubMed ID: 31680398
    [Abstract] [Full Text] [Related]

  • 15. Early Injection of Furosemide Increases Detection Rate of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT.
    Uprimny C, Bayerschmidt S, Kroiss AS, Fritz J, Nilica B, Svirydenka H, Decristoforo C, von Guggenberg E, Horninger W, Virgolini IJ.
    J Nucl Med; 2021 Nov 01; 62(11):1550-1557. PubMed ID: 33712533
    [Abstract] [Full Text] [Related]

  • 16. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.
    Franklin A, Yaxley WJ, Raveenthiran S, Coughlin G, Gianduzzo T, Kua B, McEwan L, Wong D, Delahunt B, Egevad L, Samaratunga H, Brown N, Parkinson R, Roberts MJ, Yaxley JW.
    BJU Int; 2021 Jan 01; 127(1):71-79. PubMed ID: 32524748
    [Abstract] [Full Text] [Related]

  • 17. Recurrent prostate cancer: combined role for MRI and PSMA-PET in 68Ga-PSMA-11 PET/MRI.
    Jannusch K, Bruckmann NM, Morawitz J, Boschheidgen M, Quick HH, Herrmann K, Fendler WP, Umutlu L, Stuschke M, Hadaschik B, Antoch G, Schimmöller L, Kirchner J.
    Eur Radiol; 2024 Jul 01; 34(7):4789-4800. PubMed ID: 38038758
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of early imaging with 68Ga-PSMA-I&T in the discrimination of pelvic lesions in prostate cancer patients.
    Özülker F.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019 Jul 01; 38(2):100-105. PubMed ID: 30514659
    [Abstract] [Full Text] [Related]

  • 19. Comparison of parametric imaging and SUV imaging with [68 Ga]Ga-PSMA-11 using dynamic total-body PET/CT in prostate cancer.
    Chen R, Ng YL, Yang X, Zhu Y, Li L, Zhao H, Zhou Y, Huang G, Liu J.
    Eur J Nucl Med Mol Imaging; 2024 Jan 01; 51(2):568-580. PubMed ID: 37792025
    [Abstract] [Full Text] [Related]

  • 20. Incremental Impact of [68 Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI.
    Szigeti F, Schweighofer-Zwink G, Meissnitzer M, Hauser-Kronberger C, Hitzl W, Kunit T, Forstner R, Pirich C, Beheshti M.
    Mol Imaging Biol; 2022 Feb 01; 24(1):50-59. PubMed ID: 34519966
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.